NASDAQ: OTLK Outlook Therapeutics, Inc. 8-K

Outlook Therapeutics launches up to $100M stock offering, discloses cash down to $7.7M

Filed May 13, 2026 · Period ending May 12, 2026 · ~1 min read

Key Changes

high

Company entered new at-the-market offering to sell up to $100M of common stock through H.C. Wainwright, replacing prior BTIG program. Shares will be sold directly into market at prevailing prices, diluting existing holders.

Item 1.01 verify on EDGAR →
high

Preliminary cash position was just $7.7M as of March 31, 2026, excluding $4.5M raised in April offering. Total available liquidity approximately $12.2M suggests urgent need for additional capital.

Item 8.01 view on EDGAR →
medium

Terminated existing up to $100M ATM agreement with BTIG (dated May 2023) effective May 12, 2026, and immediately replaced it with new H.C. Wainwright program on same terms.

Item 1.02 verify on EDGAR →
low

H.C. Wainwright will receive 3% commission on gross proceeds from any shares sold. Company can terminate agreement with five business days' notice; agent can terminate immediately.

Item 1.01 verify on EDGAR →

Summary

Outlook Therapeutics disclosed a precarious cash position and immediately activated a new capital-raising mechanism. With just $7.7 million in cash at quarter-end (plus $4.5 million from April), the biotech company switched its at-the-market offering program from BTIG to H.C. Wainwright, maintaining the ability to raise up to $100 million by selling shares directly into the market.

The timing signals urgency: the company terminated its three-year-old BTIG agreement and launched the replacement program within 24 hours. For retail holders, this means dilution is likely imminent as the company needs cash to fund operations. The preliminary cash figures are unaudited and could change, but the low balance explains why management moved quickly to secure flexible financing.

Watch for actual share sales under the new program in upcoming 8-K filings. Any significant drawdowns will dilute your ownership percentage, and the stock price may face pressure as new shares hit the market. The company's burn rate and progress toward revenue-generating milestones will determine how much of the up to $100 million facility gets used.

Section-by-Section Diff

Event · Item 1.01 — Entry into a Material Definitive Agreement

~600 words

Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.

4 Added

Added ATM offering agreement high

Added in current filing · verify on EDGAR →

On May 13, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share (“Common Stock”), from time to time through H.C. Wainwright as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the “Shares”).

The company established an at-the-market equity offering program allowing it to sell up to $100 million of common stock over time through H.C. Wainwright as sales agent. This is a flexible capital-raising mechanism where shares can be sold directly into the market at prevailing prices rather than through a traditional underwritten offering. The company is not obligated to sell any shares and can control timing and pricing parameters.

Added Registration status medium

Added in current filing · verify on EDGAR →

The offering has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-278340), which was declared effective by the Securities and Exchange Commission (the “Commission”) on April 5, 2024.

The shares will be sold under an existing shelf registration statement that was declared effective in April 2024, allowing the company to access capital markets quickly without needing to file a new registration statement for each offering.

Show 2 minor / wording changes

Added Commission structure low

Added in current filing · verify on EDGAR →

The Company will pay H.C. Wainwright a commission equal to 3% of the aggregate gross proceeds of any sale of Shares under the Sales Agreement.

H.C. Wainwright will receive a 3% commission on gross proceeds from any shares sold under the agreement. This is a relatively standard fee structure for ATM offerings and means the company will net 97% of sale proceeds before other expenses.

Added Termination rights low

Added in current filing · verify on EDGAR →

The Sales Agreement may be terminated by the Company at any time upon five business days’ prior written notice to H.C. Wainwright, or by H.C. Wainwright at any time.

Either party can terminate the agreement with minimal notice requirements—the company needs five business days' notice while H.C. Wainwright can terminate immediately. This provides flexibility for both parties to exit the arrangement if market conditions or business needs change.

Event · Item 1.02 — Termination of a Material Definitive Agreement

~100 words

Item 1.02 — Termination of a Material Definitive Agreement filed; see Key Changes for terms.

1 Added

Added Termination of ATM sales agreement medium

Added in current filing · verify on EDGAR →

In connection with entering into the Sales Agreement, the Company terminated, effective May 12, 2026, its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the “Prior Sales Agreement”) with BTIG, LLC with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the “Prior ATM Program”).

The company terminated its existing at-the-market equity offering program with BTIG that allowed it to raise up to $100 million by selling shares. This termination was effective May 12, 2026, and occurred in connection with entering into a new Sales Agreement. The company will no longer sell shares under the prior program.

Event · Item 2.02 — Results of Operations and Financial Condition

~600 words

Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.

1 Added

Added Preliminary results disclaimer medium

Added in current filing · verify on EDGAR →

This amount is unaudited and preliminary, is subject to normal quarterly closing processes and accounting review, and does not present all information necessary for an understanding of the Company’s financial condition as of March 31, 2026. Actual results for the three months ended March 31, 2026 will not be finalized until a later date and may differ materially from the above estimates.

The company emphasized that the disclosed cash figure is unaudited and preliminary, subject to change through normal quarterly closing and accounting review processes. Final results for the quarter ended March 31, 2026 have not been completed and could differ materially from the preliminary estimate provided.

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.

1 Added

Added At-the-market offering agreement high

Added in current filing · verify on EDGAR →

At the Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC dated May 13, 2026

The company has entered into an at-the-market (ATM) offering agreement with H.C. Wainwright, a sales agent. This type of agreement allows the company to sell shares directly into the market over time to raise capital, rather than through a traditional underwritten offering. The arrangement provides flexibility to raise funds as needed, but will dilute existing shareholders as new shares are issued.